Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 16/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 2/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410234 | 1.00 | IGF1R (1.00) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL30197710 | 1.00 | IGF1R (1.00) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL29355553 | 1.00 | IGF1R (1.00) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12429998 | 0.97 | IGF1R (0.95) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12428871 | 0.96 | IGF1R (0.93) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12429882 | 0.95 | IGF1R (0.90) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL18719947 | 0.95 | IGF1R (0.90) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12429889 | 0.94 | IGF1R (0.88) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12429891 | 0.94 | IGF1R (0.88) | IGF1RMAPK8ALKDAPK3PRKD3 | |
| SCHEMBL12429838 | 0.94 | IGF1R (0.88) | IGF1RMAPK8ALKDAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20150374767-A1 | Treatment of Cancer | VIRTTU BIOLOGICS LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| WO-2015144808-A1 | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | disclosed |
| WO-2014175444-A1 | ANTI-NLRR1 ANTIBODY | 千葉県 (JP) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014128487-A1 | TREATMENT OF CANCER | VIRTTU BIOLOGICS LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374767-A1 | Treatment of Cancer | EGFR, ERBB2, MET | IGF1R 27/4885MAPK8 518/4885ALK 33/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | IGF1R 3025/4885MAPK8 4038/4885ALK 200/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | IGF1R 3025/4885MAPK8 4038/4885ALK 200/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | IGF1R 1/4885MAPK8 1305/4885ALK 285/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | IGF1R 3025/4885MAPK8 4038/4885ALK 200/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | IGF1R 306/4885MAPK8 1053/4885ALK 5/4885 |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | IGF1R 1585/4885MAPK8 1903/4885ALK 2497/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | IGF1R 3166/4885MAPK8 4114/4885ALK 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.